用myPKFiTCE进行个性化预防:在A型血友病患者中进行现实世界的成本效益分析
Ippazio Cosimo Antonazzo1,2, Paolo Angelo Cortesi1,2, Ezio Zanon3
1Research Centre on Public Health (CESP), University of Milan-Bicocca, 20900 Monza, Italy.
Medicina (Kaunas, Lithuania)
|January 23, 2024
概括
使用myPKFiT设备的药理动力学驱动 (PK) 预防可显著减少A型血友病患者的出血. 这种方法改善了患者管理和结果,避免了每次出血的合理成本增加.
科学领域:
- 血液学 血液学 血液学
- 药物经济学 药物经济学
- 医疗器械 医疗器械
背景情况:
- 血友病A (HA) 管理通常依赖于标准预防方案.
- 需要个性化治疗策略来优化患者的治疗结果.
- 药理动力学 (PK) 指导的预防提供了一个潜在的个性化方法.
研究的目的:
- 在意大利HA患者中使用myPKFiT设备评估PK驱动预防的有效性和成本.
- 为了比较临床结果和医疗保健资源利用在实施PK导向预防之前和之后.
- 为了确定这种方法的增量成本效益比率 (ICER).
主要方法:
- 在三个意大利血友病中心进行的观察性回顾性研究.
- 包括成年患者 (≥18岁) 中度或重度的HA.
- 使用myPKFiT设备进行PK估计,并比较预防前后的数据.
主要成果:
- 观察到平均每年出血率显著降低 -1.45 (-63.80%,p=0.0055).
- 在随访期间,因子VIII (FVIII) 摄入量略有增加,达到1.73%.
- 计算出每次避免出血的ICER为5099.89欧元.
结论:
- 将PK数据集成到临床实践中可以增强血友病A患者的管理.
- myPKFiT设备促进了PK引导的预防,从而改善了临床结果.
- 这种个性化的方法证明了在减少出血方面具有合理的成本效益.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
129
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
129
Kaplan-Meier Approach
146
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
146
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


